DS
SGMT icon

David Shaw’s Sagimet Biosciences SGMT Stock Holding History

David Shaw’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Sell
22,177
-389,393
-95% -$2.65M ﹤0.01% 4576
2026
Q1 		$2.15M Sell
411,570
-73,926
-15% -$412K ﹤0.01% 2857
2025
Q4 		$2.87M Sell
485,496
-215,745
-31% -$1.55M ﹤0.01% 2756
2025
Q3 		$4.81M Buy
701,241
+557,393
+387% +$4.52M ﹤0.01% 2239
2025
Q2 		$1.1M Buy
+143,848
New +$607K ﹤0.01% 3173

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

David Shaw's SGMT Position: Q2 2026 in Review

David Shaw reduced its Sagimet Biosciences (SGMT) stake by 95% in Q2 2026, selling an estimated $2.65M and leaving 22,177 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #4576.

David Shaw first reported a position in SGMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.81M in Q3 2025. 121 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • David Shaw held 22,177 shares of Sagimet Biosciences worth $171K as of Q2 2026.
  • David Shaw sold 389,393 Sagimet Biosciences shares in Q2 2026, an estimated $2.65M.
  • Sagimet Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4576 holding.
  • David Shaw first reported a position in Sagimet Biosciences in Q2 2025 and has held it in 5 quarters since.
  • David Shaw's Sagimet Biosciences position peaked at $4.81M in Q3 2025.
  • 121 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.